$63.54 +1.25 (%) AbbVie Inc - NYSE

Apr. 20, 2015 | 04:00 PM

Partner Headlines

  1. Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent

    Benzinga | Apr. 20, 2015 | 16:09PM EST
  2. Morningstar: Gilead Sciences To Grow Its Hepatitis C Market

    Benzinga | Apr. 18, 2015 | 11:20AM EST
  3. Receptos MS Drug Succeeds Against Ulcerative Colitis

    IBD | Apr. 16, 2015 | 10:50AM EST
  4. New drug trial results positive

    IBD | Apr. 15, 2015 | 18:38PM EST
  5. Pfizer, Biogen, AbbVie Get Good Drug-Trial News

    IBD | Apr. 15, 2015 | 11:49AM EST
  6. Solar ETFs Light The Way As Equities Post Broad Gains

    IBD | Apr. 14, 2015 | 18:32PM EST
  7. J&J Earnings Beat Estimates; Guidance Mixed

    IBD | Apr. 14, 2015 | 17:48PM EST
  8. Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern

    Benzinga | Apr. 14, 2015 | 14:45PM EST
  9. J&J Earnings Beat Estimates; Guidance Mixed

    IBD | Apr. 14, 2015 | 11:12AM EST
  10. AbbVie

    IBD | Apr. 13, 2015 | 18:53PM EST
  11. Chinese Stocks Lead Stock Market Higher

    IBD | Apr. 13, 2015 | 12:03PM EST
  12. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD | Apr. 13, 2015 | 11:19AM EST
  13. Benzinga's Top Upgrades

    Benzinga | Apr. 13, 2015 | 09:08AM EST
  14. Here's Why Imbruvica Caused BMO To Upgrade AbbVie

    Benzinga | Apr. 13, 2015 | 09:04AM EST
  15. BMO Capital Upgrades AbbVie To Outperform

    Benzinga | Apr. 13, 2015 | 08:03AM EST
  16. Pioneer Fundamental Growth Fund: Why Is It Revving Up?

    IBD | Mar. 3, 2015 | 17:22PM EST
  17. Cyberonics Soars On Earnings Beat, Tax Inversion Deal

    IBD | Feb. 26, 2015 | 13:58PM EST
  18. Making Money With Charles Payne: 02/25/15

    FoxBusiness | Feb. 25, 2015 | 18:00PM EST
  19. Heavy News Day For Several Biotech Stocks

    Benzinga | Feb. 25, 2015 | 15:34PM EST
  20. Catalysts AbbVie Investors Need To Watch

    Benzinga | Feb. 24, 2015 | 18:28PM EST
  21. UPDATE: Results from AbbVie's Study of VIEKIRA PAK

    Benzinga | Feb. 23, 2015 | 11:05AM EST
  22. Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepat

    Benzinga | Feb. 23, 2015 | 11:05AM EST
  23. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga | Feb. 23, 2015 | 07:34AM EST
  24. CNBC's Stock Pops & Drops From February 20

    Benzinga | Feb. 22, 2015 | 20:26PM EST
  25. Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper!

    GuruFocus | Feb. 21, 2015 | 22:55PM EST
  26. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices

    Benzinga | Feb. 20, 2015 | 13:10PM EST
  27. Soros Fund Management Sells American Express & Netflix, Buys FireEye In Q4

    Benzinga | Feb. 17, 2015 | 17:25PM EST
  28. Biotech Performance 'Particularly Impressive,' Says JP Morgan

    Benzinga | Feb. 17, 2015 | 13:30PM EST
  29. Salix, Top Drug Stocks Rally As Merger Mania Heats Up

    IBD | Feb. 13, 2015 | 18:08PM EST
  30. Shire Moves Higher On NPS Potential; Q4 Earnings Miss

    IBD | Feb. 12, 2015 | 10:45AM EST
  31. US Stock Futures Up Ahead Of Jobless Claims, Retail Sales Data

    Benzinga | Feb. 12, 2015 | 07:30AM EST
  32. Deutsche Bank's 7 Reasons AbbVie Is Still A Buy

    Benzinga | Feb. 11, 2015 | 12:54PM EST
  33. Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial

    GuruFocus | Feb. 10, 2015 | 12:36PM EST
  34. Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown

    Benzinga | Feb. 9, 2015 | 11:46AM EST
  35. UPDATE: Citi Initiates Coverage On AbbVie, Sees Price Erosion Ahead

    Benzinga | Feb. 9, 2015 | 09:45AM EST
  36. Benzinga's Top Initiations

    Benzinga | Feb. 9, 2015 | 09:25AM EST
  37. Citigroup Initiates AbbVie With Sell

    Benzinga | Feb. 9, 2015 | 08:38AM EST
  38. Barron's Recap: This Man Made, Lost And Made A Fortune Investing In Russia

    Benzinga | Feb. 8, 2015 | 11:09AM EST
  39. Andreas Halvorsen's Trades Of January 2015

    GuruFocus | Feb. 6, 2015 | 11:25AM EST
  40. Gilead Sciences Offering Fresh Wave Of Competition To AbbVie's Viekira Pak

    GuruFocus | Feb. 6, 2015 | 10:59AM EST
  41. Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015

    GuruFocus | Feb. 5, 2015 | 11:35AM EST
  42. Merck hep C drug faces delays

    IBD | Feb. 4, 2015 | 19:29PM EST
  43. Gilead

    IBD | Feb. 4, 2015 | 19:28PM EST
  44. HCV Stocks Struggle As Gilead, Merck Face Headwinds

    IBD | Feb. 4, 2015 | 12:12PM EST
  45. AbbVie's Q4 Reflects Its Tremendous Growth Potential Going Forward

    GuruFocus | Feb. 4, 2015 | 11:58AM EST
  46. Gilead Q4 Earnings Beat, But Price War Taking Toll

    IBD | Feb. 3, 2015 | 19:26PM EST
  47. Looking Ahead of Wall Street: Gilead Sciences, Chipotle, Twitter

    GuruFocus | Feb. 3, 2015 | 18:27PM EST
  48. UBS Thinks AbbVie's Valuation Is 'Interesting'

    Benzinga | Feb. 2, 2015 | 11:18AM EST
  49. Cramer Advises Viewers On Mattel, Linn Energy And AbbVie

    Benzinga | Feb. 1, 2015 | 12:57PM EST
  50. Viekira Pak View Falls Short

    IBD | Jan. 30, 2015 | 18:41PM EST
Trading Center